|Articles|February 29, 2020
NeurologyLive Friday 5 — February 28, 2020
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 28, 2020.
Advertisement
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Evidence Lacking for Cognitive Screening in Older Adults, USPSTF Says
Based on current evidence, the Task Force was unable to recommend cognitive screening for older adults despite a recent push by the AAN to screen all adults 65 and older for thinking and memory problems.
2: How an Innovative Trial Design May Change the ALS Treatment Landscape
The Healey ALS Platform Trial learns from successful cancer drug studies to identify and accelerate new treatments for the devastating disease.
3: Evolution of MS MRI Guidelines and Alignment With MAGNIMS
Multiple sclerosis experts discuss the 2019 Consortium of Multiple Sclerosis Center Annual Meeting, the development of MRI protocol and clinical guidelines, and alignment with the MAGNIMS protocol.
4: Mission Control: Cleveland Clinic's Hub of Epilepsy Expertise Has Global Benefits
Imad Najm, MD, director of the Cleveland Clinic Epilepsy Center, detailed the ongoing efforts to transform the way health care providers diagnose and treat patients with 1 ultimate goal in mind: improving access to high-quality care.
5: Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration
Patients with a disease duration of <16 years experienced a significantly greater reduction in risk for confirmed disability progression at 3 and 6 months compared with placebo.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Expanding the Alzheimer Drug Development PipelineSeptember 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome
5
